Small molecule · Cytotoxic, directed at DNA · developed by Sanofi Aventis Us
Oxaliplatin is an organoplatinum complex that is converted in physiologic solutions to reactive derivatives which form inter- and intrastrand platinum-DNA crosslinks. These crosslinks inhibit DNA replication and transcription in a cell-cycle nonspecific manner. It is studied in colorectal cancer and peripheral T-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04984837 | Phase 2 | Peripheral T Cell Lymphoma | Active not recruiting | IPHA |
| NCT03428958 | Phase 1/2 | Colorectal Cancer | Completed | NCNA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Peripheral T Cell LymphomaRelapse/RecurrenceColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsNeoplasms, Colorectal